Author: Saeed, Abdullah F. U. H.; Wang, Rongzhi; Ling, Sumei; Wang, Shihua
Title: Antibody Engineering for Pursuing a Healthier Future Document date: 2017_3_28
ID: 0fegsm1v_9
Snippet: Polyclonal antibodies (pAbs) can be produced rapidly in several months (compared to monoclonal antibodies), with low cost, low technical skill, and these are stable over a broad range of pH and salt concentrations. In addition, they have applications as therapeutic immunoglobulins (Lipman et al., 2005) . PAbs recognize multiple linear epitopes with minimal conformational changes and contain numerous antibodies of varying affinities, which are use.....
Document: Polyclonal antibodies (pAbs) can be produced rapidly in several months (compared to monoclonal antibodies), with low cost, low technical skill, and these are stable over a broad range of pH and salt concentrations. In addition, they have applications as therapeutic immunoglobulins (Lipman et al., 2005) . PAbs recognize multiple linear epitopes with minimal conformational changes and contain numerous antibodies of varying affinities, which are useful for the immunoprecipitation of composite FIGURE 1 | Interaction of antibodies with numerous antigens present on the surface of target cell. (A) Interaction of polyclonal antibodies with specific surface antigen activates B lymphocytes to divide and differentiate into plasma cell clones producing more antibodies that recognize antigens. (B) Interaction of monoclonal antibodies with specific surface antigen activates B lymphocytes to divide and differentiate into plasma cell clones that further recruit homogeneous and mono-specific antibodies.
Search related documents:
Co phrase search for related documents- monoclonal antibody and plasma cell: 1, 2, 3, 4, 5, 6
- monoclonal antibody and polyclonal antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- monoclonal antibody and rapidly produce: 1, 2
- monoclonal antibody and specific surface: 1, 2, 3, 4, 5, 6, 7, 8
- monoclonal antibody and target cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- monoclonal antibody and target cell surface: 1
- pAbs Polyclonal antibody and polyclonal antibody: 1
- plasma cell and polyclonal antibody: 1, 2, 3
- plasma cell and rapidly produce: 1
- plasma cell and specific surface: 1, 2, 3, 4
- plasma cell and target cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- plasma cell and target cell surface: 1, 2
- polyclonal antibody and specific surface: 1
- polyclonal antibody and therapeutic immunoglobulin: 1, 2
- specific surface and target cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- specific surface and target cell surface: 1, 2, 3, 4, 5, 6, 7
- specific surface and therapeutic immunoglobulin: 1
Co phrase search for related documents, hyperlinks ordered by date